Concepedia

Mary Kay Schultz

MK

Statistics

Publications

4

Citations

317

H-Index

4

Active since

2006

Affiliations

University of Colorado Denver(Current)

University of Colorado Cancer Center

Mary Kay Schultz is an author at University of Colorado Denver specializing in cancer pharmacology, pharmacology, and oncology pharmacotherapy.

Publications per year

2006–2010

4

Publications

4

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Lia Gore, Mace L. Rothenberg, Cindy L. O’Bryant et al. · Clinical Cancer Research · 2008 · 173 citations · Full text

Medicine, Oncology, Pharmacology +12

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

M. Basche, Daniel L. Gustafson, Scott N. Holden et al. · Clinical Cancer Research · 2006 · 95 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

Laura Q.M. Chow, Sabine Eckhardt, Cindy L. O’Bryant et al. · Cancer Chemotherapy and Pharmacology · 2007 · 25 citations · Full text

Medicine, Oncology, Pharmacology +10

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

Thomas W. Flaig, Luciano J. Costa, Daniel L. Gustafson et al. · British Journal of Cancer · 2010 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

1–4 of 4